Cancer Diagnostics Market to Reach USD 148.2 Billion by 2035 Driven by AI, Liquid Biopsies & Early Detection

The global cancer diagnostics market is entering a decade of unprecedented growth, projected to nearly double in value from USD 65.5 billion in 2025 to USD 148.2 billion by 2035. This expansion, reflecting a strong compound annual growth rate (CAGR) of 8.5%, highlights the pivotal role of diagnostics in advancing early cancer detection, precision oncology, and treatment monitoring worldwide.

Market Growth Supported by Innovation

Between 2025 and 2030, the market is expected to cross USD 98.5 billion, with growth largely driven by the rising adoption of advanced technologies such as multi-cancer early detection (MCED) tests, liquid biopsies, next-generation sequencing, and AI-powered imaging systems. These innovations are enabling healthcare providers to diagnose cancers earlier and more accurately, improving patient survival rates. Over the 2025-2035 forecast period, the industry is projected to generate USD 82.7 billion in new opportunities, underscoring the scale of transformation underway. Established players like F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Abbott Laboratories, and Siemens Healthineers continue to lead through partnerships, product launches, and AI-driven molecular diagnostics. At the same time, innovative firms such as Guardant Health and Illumina are disrupting the market with breakthroughs in genomic sequencing and liquid biopsy applications.

Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-1090

Key Drivers of Market Expansion

The growth of the cancer diagnostics market is supported by several important factors. Early detection has been proven to save lives, and rising awareness among both patients and healthcare systems is ensuring that screening programs are more widely implemented. The integration of artificial intelligence into medical imaging and genomics has accelerated the speed, accuracy, and reliability of diagnostic processes, reducing misdiagnosis rates. The increasing preference for minimally invasive testing is also shaping demand, with liquid biopsies and circulating tumor DNA analysis offering safer and more patient-friendly alternatives to traditional biopsies. In addition, global awareness campaigns, government initiatives, and expanded insurance coverage are making cancer testing more accessible to larger populations.

Segmental Insights

Hospitals and diagnostic centers continue to dominate the end-user landscape, accounting for nearly 45% of the market share in 2025. Their central role stems from their ability to provide multidisciplinary care through oncologists, pathologists, and radiologists, making them the primary centers for both diagnosis and treatment planning. Within indications, breast cancer remains the leading segment, with nearly 20% of the market share in 2025. This dominance is driven by widespread mammography adoption, the rise of genetic testing, and the integration of digital breast tomosynthesis. As screening programs for women's health continue to expand, the demand for breast cancer diagnostics will remain strong.

Test type preferences are also evolving. While traditional tissue-based biopsies are still widely used, liquid biopsies are experiencing rapid uptake due to their accuracy, convenience, and ability to provide tumor profiling. These tests are particularly useful for treatment monitoring, early detection of relapse, and minimal residual disease analysis, positioning them as game-changers in oncology diagnostics.

Regional Market Outlook

Regionally, the cancer diagnostics market is experiencing varied growth patterns. India is emerging as the fastest-growing country, with a projected CAGR of 6.8%. Urbanization, government healthcare programs, and the rising incidence of cancer are pushing demand for cost-effective and reliable diagnostics. China follows closely with a 5.6% CAGR, driven by state-backed healthcare reforms, expanded insurance coverage, and growing adoption of early detection tools in urban centers. South Korea, with its well-established cancer screening programs and biomarker-driven research, is expected to achieve 5.4% growth.

In Europe, both the United Kingdom and France continue to expand steadily, with CAGRs of 4.4 and 4.0% respectively. The UK's National Health Service (NHS) plays a crucial role in expanding genomic testing, while France's investment in digital health and molecular diagnostics strengthens its outlook. Japan is also maintaining steady growth, with a 4.2% CAGR, supported by its adoption of AI-powered imaging and genomic tools. Meanwhile, the United States remains the global hub for innovation, growing at a CAGR of 4.0%. The country's focus on precision medicine, genetic testing, and AI-enhanced imaging makes it one of the most influential players in shaping the market's future. Germany, with a CAGR of 3.9%, reflects a mature but steadily growing market supported by strong insurance frameworks and digital pathology adoption.

Market Significance Across Healthcare

Cancer diagnostics are not only central to oncology but also form a substantial part of broader healthcare diagnostics. In 2025, cancer testing is expected to represent 18.4% of the global healthcare diagnostics market, 22.8% of molecular diagnostics, and 15.6% of medical imaging. Within oncology care systems, diagnostics will account for nearly 28.7% of the value chain, highlighting their indispensable role in early detection and personalized treatment. Even in point-of-care diagnostics, cancer-related tests are becoming increasingly common, representing 9.2% of the segment.

Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/cancer-diagnostics-market

Opportunities and Challenges

The coming decade will present significant opportunities for the industry. Multi-cancer early detection tests are expected to deliver up to 40% higher detection rates, making population-wide screening a possibility. Smart diagnostics, powered by artificial intelligence, the Internet of Things, and cloud-based platforms, are revolutionizing real-time monitoring and reporting. Personalized oncology is advancing rapidly, with diagnostics tailored to specific genetic and biomarker profiles, enabling oncologists to match patients with targeted therapies.

However, the market faces challenges. Advanced diagnostic systems remain costly, often priced 50 to 70% higher than conventional methods, limiting accessibility in low- and middle-income regions. Regulatory hurdles also persist, as lengthy validation timelines can delay commercialization by up to five years. Additionally, there is a shortage of skilled molecular diagnostics professionals, particularly in emerging economies, which poses a challenge to widespread adoption.

Competitive Landscape

The competitive environment in cancer diagnostics is diverse, comprising global leaders, diversified healthcare firms, emerging innovators, and regional specialists. Roche, Abbott, Thermo Fisher, and Siemens Healthineers maintain leadership positions with extensive portfolios across imaging, pathology, and molecular testing. GE Healthcare and Philips strengthen the sector through advanced imaging solutions that complement oncology care. On the innovation front, companies like Guardant Health and Illumina are rapidly advancing liquid biopsy, sequencing, and circulating tumor DNA technologies. Regional players across Asia and Europe are addressing accessibility challenges with cost-effective diagnostic models, ensuring that innovation is not limited to high-income markets.

Related Reports:

Next-Generation Titrators Market: https://www.futuremarketinsights.com/reports/next-generation-titrators-market

Cancer-Focused Genetic Testing Services Market: https://www.futuremarketinsights.com/reports/cancer-focused-genetic-testing-services-market

Juvenile Idiopathic Arthritis Diagnostic Market: https://www.futuremarketinsights.com/reports/juvenile-idiopathic-arthritis-diagnostics-market

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.